Eli Lilly $4 billion notes offering
The investment-grade notes are due 2026, 2033, 2053 and 2063
Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $4 billion aggregate principal amount of senior notes, consisting of $750 million of its 5.000% notes due 2026, $1 billion of its 4.700% notes due 2033, $1.25 billion of its 4.875% notes due 2053 and $1 billion of its 4.950% notes due 2063.
Eli Lilly and Company is a worldwide research-based pharmaceutical company. The company has been pioneering life-changing discoveries for nearly 150 years, and today its medicines help more than 47 million people across the globe. It is focused on discovering, developing, manufacturing and marketing products in a single business segment—human pharmaceutical products.
The Davis Polk capital markets team included partner Yasin Keshvargar, counsel Jennifer Ying Lan and associate Joyce Kim. The tax team included partner Mario J. Verdolini and associate Tyler Scheiner. The environmental team included counsel Loyti Cheng and Michael Comstock. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. All members of the Davis Polk team are based in the New York office.